Patients with the most severe form of inherited high cholesterol now face a critical double threat as they live longer lives. While aggressive cholesterol-lowering treatments have extended survival in homozygous familial hypercholesterolemia, this improvement creates new vulnerability to conventional heart disease triggers that were previously overshadowed by extreme cholesterol levels.
Analysis of 912 patients from the international HICC registry reveals that hypertension nearly doubles coronary artery disease risk in this population, with an 85% increased odds ratio after controlling for other factors. The finding emerges from patients across multiple countries, with a median age of 33 years. Surprisingly, diabetes, smoking, and obesity showed no significant association with heart disease outcomes, despite their established roles in the general population. Traditional risk factors appeared more frequently in older patients and paradoxically in those achieving better cholesterol control through treatment.
This data fundamentally shifts clinical priorities for a condition affecting roughly one in 300,000 individuals. As lipid-lowering therapies including PCSK9 inhibitors and lomitapide extend lifespans, clinicians must now aggressively manage blood pressure alongside cholesterol. The research suggests that achieving ultra-low LDL cholesterol levels may unmask hypertension as the dominant modifiable risk factor. However, the cross-sectional design cannot establish causation, and the relatively young cohort limits long-term outcome predictions. The finding represents a paradigm shift from single-target therapy toward comprehensive cardiovascular risk management in this rare but instructive genetic condition.